UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5649) 5649
Newsletter (304) 304
Book Chapter (42) 42
Newspaper Article (39) 39
Dissertation (13) 13
Publication (8) 8
Conference Proceeding (6) 6
Magazine Article (6) 6
Reference (2) 2
Book / eBook (1) 1
Book Review (1) 1
Government Document (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3964) 3964
science & technology (3786) 3786
erlotinib (3751) 3751
life sciences & biomedicine (3595) 3595
erlotinib hydrochloride (2721) 2721
oncology (2536) 2536
lung neoplasms - drug therapy (2080) 2080
female (1922) 1922
carcinoma, non-small-cell lung - drug therapy (1765) 1765
male (1688) 1688
quinazolines - therapeutic use (1472) 1472
middle aged (1453) 1453
receptor, epidermal growth factor - antagonists & inhibitors (1390) 1390
aged (1337) 1337
cancer (1208) 1208
protein kinase inhibitors - therapeutic use (1190) 1190
lung cancer, non-small cell (1125) 1125
antineoplastic agents - therapeutic use (1089) 1089
mutation (1008) 1008
gefitinib (990) 990
lung neoplasms - pathology (985) 985
lung cancer (965) 965
adult (947) 947
care and treatment (934) 934
epidermal growth factor (919) 919
receptor, epidermal growth factor - genetics (910) 910
lung neoplasms - genetics (885) 885
treatment outcome (840) 840
quinazolines - administration & dosage (836) 836
research (832) 832
antineoplastic combined chemotherapy protocols - therapeutic use (754) 754
carcinoma, non-small-cell lung - pathology (753) 753
quinazolines - pharmacology (744) 744
chemotherapy (735) 735
animals (721) 721
carcinoma, non-small-cell lung - genetics (704) 704
cell line, tumor (704) 704
quinazolines - adverse effects (660) 660
aged, 80 and over (632) 632
egfr (617) 617
protein kinase inhibitors - pharmacology (612) 612
non-small cell lung cancer (595) 595
respiratory tract diseases (595) 595
receptor, epidermal growth factor - metabolism (553) 553
epidermal growth factor receptor (537) 537
antineoplastic agents - pharmacology (511) 511
analysis (508) 508
pharmacology & pharmacy (492) 492
tyrosine (491) 491
respiratory system (489) 489
adenocarcinoma - drug therapy (483) 483
disease-free survival (473) 473
mice (471) 471
drug therapy (470) 470
cetuximab (439) 439
erlotinib hydrochloride - therapeutic use (435) 435
neoplasm staging (430) 430
bevacizumab (420) 420
hematology, oncology and palliative medicine (419) 419
protein kinase inhibitors - adverse effects (413) 413
prognosis (400) 400
metastasis (382) 382
lung neoplasms - mortality (378) 378
neoplasms (366) 366
health aspects (362) 362
carcinoma, non-small-cell lung - mortality (347) 347
protein kinase inhibitors - administration & dosage (343) 343
antineoplastic agents - adverse effects (341) 341
antibodies, monoclonal, humanized (340) 340
genetic aspects (340) 340
nsclc (340) 340
erlotinib hydrochloride - administration & dosage (338) 338
oncology, experimental (336) 336
clinical trials (334) 334
pancreatic cancer (326) 326
lung neoplasms - metabolism (325) 325
tumors (319) 319
erlotinib hydrochloride - pharmacology (318) 318
kinases (314) 314
cancer therapies (307) 307
erbb receptors - antagonists & inhibitors (307) 307
medicine & public health (306) 306
deoxycytidine - analogs & derivatives (300) 300
drug resistance, neoplasm (294) 294
lung cancer, small cell (289) 289
erbb receptors - genetics (288) 288
retrospective studies (285) 285
antineoplastic agents - administration & dosage (279) 279
survival rate (278) 278
pulmonary/respiratory (276) 276
cell proliferation - drug effects (270) 270
epidermal growth factor receptors (269) 269
pancreatic neoplasms - drug therapy (267) 267
dosage and administration (258) 258
antibodies, monoclonal - therapeutic use (254) 254
patients (254) 254
carcinoma, non-small-cell lung - metabolism (250) 250
survival analysis (249) 249
signal transduction - drug effects (248) 248
disease progression (241) 241
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5708) 5708
French (114) 114
Chinese (92) 92
Japanese (59) 59
German (58) 58
Korean (37) 37
Spanish (33) 33
Portuguese (23) 23
Czech (11) 11
Hungarian (10) 10
Russian (8) 8
Polish (6) 6
Turkish (6) 6
Dutch (5) 5
Italian (4) 4
Danish (3) 3
Norwegian (2) 2
Croatian (1) 1
Romanian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Molecular imaging and biology, ISSN 1860-2002, 10/2018, Volume 21, Issue 4, pp. 696 - 704
Journal Article
Investigational new drugs, ISSN 0167-6997, 4/2017, Volume 35, Issue 2, pp. 242 - 246
Journal Article
Investigational new drugs, ISSN 0167-6997, 2/2017, Volume 35, Issue 1, pp. 95 - 104
Advanced biliary tract cancers (ABTC) are among the deadliest malignancies with limited treatment options after progression on standard-of-care chemotherapy,... 
Gemcitabine and oxaliplatin | Medicine & Public Health | Oncology | Pharmacology/Toxicology | Phase Ib trial | Biliary tract cancers | Pulsatile erlotinib | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Science & Technology | Receptor, Epidermal Growth Factor - genetics | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Cadherins - metabolism | Proto-Oncogene Proteins p21(ras) - genetics | Vimentin - metabolism | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Deoxycytidine - therapeutic use | Organoplatinum Compounds - administration & dosage | Antineoplastic Agents - adverse effects | Biliary Tract Neoplasms - metabolism | Aged, 80 and over | Adult | Deoxycytidine - adverse effects | Female | Biliary Tract Neoplasms - drug therapy | Biliary Tract Neoplasms - genetics | Erlotinib Hydrochloride - adverse effects | Drug Administration Schedule | Deoxycytidine - administration & dosage | Erlotinib Hydrochloride - administration & dosage | Kaplan-Meier Estimate | Treatment Outcome | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Erlotinib Hydrochloride - therapeutic use | Mutation | Organoplatinum Compounds - therapeutic use | Deoxycytidine - analogs & derivatives | Organoplatinum Compounds - adverse effects | Dose-response relationship (Biochemistry) | Drug therapy, Combination | Gemcitabine | Erlotinib | Patient outcomes | Methods | Chemotherapy | Statistical analysis | Toxicity | Response rates | Clinical trials | Drug therapy | Cancer therapies | Drug dosages | Patients | Cancer | Index Medicus | Phase I Studies
Journal Article
Journal Article
by Wu, Y.-L and Zhou, C and Liam, C.-K and Wu, G and Liu, X and Zhong, Z and Lu, S and Cheng, Y and Han, B and Chen, L and Huang, C and Qin, S and Zhu, Y and Pan, H and Liang, H and Li, E and Jiang, G and How, S.H and Fernando, M.C.L and Zhang, Y and Xia, F and Zuo, Y
Annals of oncology, ISSN 0923-7534, 09/2015, Volume 26, Issue 9, pp. 1883 - 1889
Journal Article
Indian Journal of Medical Research, ISSN 0971-5916, 1/2019, Volume 150, Issue 1, pp. 67 - 72
Background & objectives: Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR) have been evaluated in patients with advanced... 
Immunology | Life Sciences & Biomedicine | Medicine, General & Internal | General & Internal Medicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Humans | Middle Aged | ErbB Receptors - genetics | Male | Drug-Related Side Effects and Adverse Reactions - pathology | Erlotinib Hydrochloride - economics | Adult | Female | Carcinoma, Non-Small-Cell Lung - pathology | ErbB Receptors - antagonists & inhibitors | Protein Kinase Inhibitors - economics | Carcinoma, Non-Small-Cell Lung - genetics | Erlotinib Hydrochloride - administration & dosage | Kaplan-Meier Estimate | Gefitinib - economics | Drug-Related Side Effects and Adverse Reactions - epidemiology | Carcinoma, Non-Small-Cell Lung - economics | Protein Kinase Inhibitors - administration & dosage | Mutation - drug effects | Cost-Benefit Analysis | Progression-Free Survival | Aged | Gefitinib - administration & dosage | Carcinoma, Non-Small-Cell Lung - drug therapy | Smoking | Carcinoma | Erlotinib | Patient outcomes | Comparative analysis | Gefitinib | Lung cancer, Non-small cell | Drug therapy | Cancer | Studies | Cellular biology | Lung cancer | Mutation | Females | Patients | Cancer therapies | Drug dosages | Age | Tumors | Index Medicus | non-small cell lung cancer | erlotinib | treatment response | gefitinib | pharmacoeconomic analysis | Original | Epidermal growth factor receptor inhibitors | Epidermal growth factor receptor inhibitors - erlotinib - gefitinib - non-small cell lung cancer - pharmacoeconomic analysis - treatment response
Journal Article
Journal Article
Journal Article
Journal of controlled release, ISSN 0168-3659, 05/2016, Volume 229, pp. 80 - 92
Pretreatment of lung cancer cells with epidermal growth factor receptor (EGFR) inhibitor erlotinib has been recently reported that could dramatically synergize... 
pH-sensitive | Charge conversion | MSN | Erlotinib | DOX | Synergistic therapy | Pharmacology & Pharmacy | Physical Sciences | Chemistry | Life Sciences & Biomedicine | Chemistry, Multidisciplinary | Science & Technology | Doxorubicin - therapeutic use | Drug Carriers - therapeutic use | Nanoparticles - chemistry | Apoptosis - drug effects | Benzoates - chemistry | Humans | Erlotinib Hydrochloride - chemistry | Drug Carriers - administration & dosage | Male | Antineoplastic Agents - therapeutic use | Doxorubicin - chemistry | Antineoplastic Agents - administration & dosage | Drug Carriers - chemistry | Protein Kinase Inhibitors - chemistry | Nanoparticles - therapeutic use | Antineoplastic Agents - pharmacokinetics | Drug Therapy, Combination | Doxorubicin - administration & dosage | Protein Kinase Inhibitors - pharmacokinetics | A549 Cells | Cell Survival - drug effects | Erlotinib Hydrochloride - pharmacokinetics | Mice, Inbred C57BL | Erlotinib Hydrochloride - administration & dosage | Phosphatidylcholines - chemistry | Antineoplastic Agents - chemistry | Rats, Sprague-Dawley | Doxorubicin - pharmacokinetics | Carcinoma, Lewis Lung - drug therapy | Drug Synergism | Protein Kinase Inhibitors - administration & dosage | Animals | Drug Liberation | Drug Carriers - pharmacokinetics | Erlotinib Hydrochloride - therapeutic use | Nanoparticles - administration & dosage | Hydrogen-Ion Concentration | Membrane lipids | Anthracyclines | Epidermal growth factor | Hydrogen-ion concentration | Lung cancer | Surface active agents | Drug discovery | Index Medicus
Journal Article